|
|
Article: SCYNEXIS and Genecare Research Institute Sign Anti-Inflammatory Drug Discovery Deal.
- Article from:
- PR Newswire
- Article date:
- December 8, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RESEARCH TRIANGLE PARK, N.C., Dec. 8 /PRNewswire/ -- SCYNEXIS Europe and GeneCare Research Institute Co Ltd in Kamakura, Japan, have announced details of a new deal between the two companies.
Under the terms of the agreement, SCYNEXIS will provide a range of drug discovery, synthesis and purification services to support GeneCare Research Institute's on-going work in the field of anti-inflammatory drugs. Using SCYNEXIS's proprietary HEOS(TM) operating system, hit explosion work will be undertaken to develop high-purity compound libraries for subsequent screening by GeneCare Research Institute. HEOS(TM) will also be used for rapid lead optimization to identify ...